Terrence Wright, MD
Family Medicine · Grand Rapids, MINPI 1124056643
Payments from drug & device makers
Across 239 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$666
- Novo Nordisk$585
- AstraZeneca$481
- Pfizer$260
- Lilly USA, LLC$167
- Takeda Pharmaceuticals U.S.A., Inc.$152
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,487100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $666 |
| Novo Nordisk | 40 | $585 |
| AstraZeneca | 29 | $481 |
| Pfizer | 28 | $260 |
| Lilly USA, LLC | 10 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $152 |
| GSK | 10 | $147 |
| E.r. Squibb & Sons, L.L.C. | 7 | $143 |
| Amgen | 8 | $124 |
| Merck | 5 | $103 |
| Novartis | 5 | $84 |
| Astellas Pharma US Inc | 4 | $80 |
| Johnson & Johnson | 6 | $80 |
| Boehringer Ingelheim | 5 | $74 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Cranial Technologies, Inc | 1 | $12 |
How this compares
$3,493 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $109,435 |
| TrulicityDulaglutide | 48 | $66,111 |
| XareltoRivaroxaban | 28 | $33,652 |
| FarxigaDapagliflozin Propanediol | 30 | $30,623 |
| JardianceEmpagliflozin | 25 | $26,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $24,427 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $15,547 |
| LinzessLinaclotide | 19 | $13,437 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $12,208 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $10,882 |
| TrintellixVortioxetine Hydrobromide | 12 | $10,615 |
| DuleraMometasone/Formoterol | 18 | $10,389 |
| OzempicSemaglutide | 11 | $10,190 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,689 |
| Levothyroxine Sodium | 299 | $6,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $260 | $109,435100 claims |
| Lilly USA, LLCTrulicity | $167 | $66,11148 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $147 | $39,97444 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $481 | $39,31243 claims |
| Johnson & JohnsonXarelto | $80 | $33,65228 claims |
| Boehringer IngelheimJardiance | $74 | $26,22725 claims |
| AbbVieLinzess, Synthroid | $666 | $14,47946 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $152 | $10,61512 claims |
| MerckDulera | $103 | $10,38918 claims |
| Novo NordiskOzempic | $585 | $10,19011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Grand Rapids
- Rhonda MejeurGrand Rapids$493K
- Mary DagenGrand Rapids$265K
- Nirali BoraGrand Rapids$133K
- Oren MasonGrand Rapids$97K
- Magalis LlovetGrand Rapids$21K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.